SCHEMBL16208435

SCHEMBL16208435

Cc1cccc(NC(=O)CSc2nc3cccnc3[nH]2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 2/20 0.73
▸ LMNA P02545 3/20 0.60
▸ HTT P42858 1/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ MAPT P10636 5/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ TP53 P04637 2/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ NPC1 O15118 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.54
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16208440 0.88 MPO (0.71) MPOLMNAHTTSMN1; SMN2MAPT
SCHEMBL16208409 0.86 TSHR (0.59) MPOLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL17712438 0.84 MAPT (0.64) MPOLMNAMAPTTP53POLB
SCHEMBL6211513 0.83 MPO (0.77) MPOLMNAHTTSMN1; SMN2MAPK1
SCHEMBL20305142 0.82 ENPP1 (0.74) LMNAHTTSMN1; SMN2ALDH1A1TDP1
SCHEMBL16208365 0.81 MAPT (0.56) MPOLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL17624905 0.79 MAPT (0.74) MPOLMNASMN1; SMN2MAPK1MAPT
SCHEMBL20067989 0.75 ALDH1A1 (0.70) MPOLMNAHTTSMN1; SMN2MAPT
SCHEMBL16208389 0.75 MPO (0.72) MPOLMNAHTTSMN1; SMN2MAPK1
SCHEMBL22639839 0.74 KMT2A (0.78) MPOLMNAHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 — — US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A MPO 981/4885LMNA 4827/4885HTT 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback